Metabolomics reveal distinct molecular pathways associated with future risk of Crohn’s Disease
Mingyue Xue(Mount Sinai Hospital), Mark S. Silverberg(Sinai Health System), Williams Turpin(Mount Sinai Hospital), Remo Panaccione(University of Calgary), Haim Leibovitzh(Tel Aviv Sourasky Medical Center), Jingchen Shao(Max Planck Institute for Heart and Lung Research), Çharles N. Bernstein(University of Manitoba), Mark J. Ropeleski, H Huynh(University of Alberta), David R. Mack(University of Ottawa), Alain Bitton(McGill University Health Centre), Osvaldo Espin‐Garcia(Western University), Kenneth Croitoru(University of Toronto), Karen Madsen(University of Alberta), Kevan Jacobson(Immune Deficiency Foundation), Colette Deslandres(Centre Hospitalier Universitaire Sainte-Justine), Paul Moayyedi(McMaster University Medical Centre), Wei Xu(Obstetrics and Gynecology Hospital of Fudan University), Brian Bressler(University of British Columbia), Anne M. Griffiths(University of Toronto), A. Hillary Steinhart(Mount Sinai Hospital), Guy Aumais, Dan Turner(Shaare Zedek Medical Center), Maria Cino, Sun-Ho Lee(Mount Sinai Hospital)
Cited by 6
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k